Replimune Q3 net loss $70.9M; cash $269.1M; RP1 BLA PDUFA date April 10, 2026

Replimune Group, Inc.

2026-Q3 EPS reported -$2.62

Cash, cash equivalents, and short-term investments $269.1M as of Dec 31, 2025; cash runway extended late into Q1 2027.
Net loss for Q3 FY2026 was $70.9M vs $66.3M in prior year quarter; R&D expenses $53.1M.
BLA resubmission for RP1 in anti-PD-1 failed melanoma accepted; FDA PDUFA target action date April 10, 2026.
Amended loan with Hercules: drew $35M, potential additional $120M post-approval; debt repayment delayed to 2027.
Phase 3 IGNYTE-3 confirmatory study for RP1 enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma actively enrolling.

item 1.01 item 2.02 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Replimune Group, Inc. amended credit facility with Hercules Capital, Inc. at greater of either (i) 8.50% and (ii) the Prime Rate (as defined in the Loan Agre.

Instrument: credit facility
Counterparty: Hercules Capital, Inc.
Rate: greater of either (i) 8.50% and (ii) the Prime Rate (as defined in the Loan Agre
Event: amendment

Exact text from the filing

the interest rate was amended to be equal to the greater of either (i) 8.50% and (ii) the Prime Rate (as defined in the Loan Agreement) plus 1.75%, and the amortization date was extended from October 1, 2026 to October 1, 2027

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Replimune Group, Inc. incurred term loan of $35 million with Hercules Capital, Inc. at greater of either (i) 8.50% and (ii) the Prime Rate (as defined in the Loan Agre.

Instrument: term loan
Principal: $35 million
Counterparty: Hercules Capital, Inc.
Rate: greater of either (i) 8.50% and (ii) the Prime Rate (as defined in the Loan Agre
Event: incurrence

Exact text from the filing

the third loan tranche advance under the Loan Agreement was increased from $30 million to $35 million and the availability of the tranche was extended until June 15, 2026

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Replimune Group, Inc. amended Third Amendment to Loan and Security Agreement with Hercules Capital, Inc. valued at $35 million (effective 2026-01-29).

Action: amendment
Agreement: credit facility
Counterparty: Hercules Capital, Inc.
Value: $35 million
Effective: 2026-01-29

Exact text from the filing

On January 29, 2026 (the “Third Amendment Closing Date”), Replimune Group, Inc. (the “Company”) and certain subsidiaries of the Company (collectively, the “Borrowers”) entered into a Third Amendment to Loan and Security Agreement (the “Amendment”) with Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent (the “Agent”), and certain other financial institutions that from time to time may become parties to the Loan Agreement as lenders (collectively, the “Lenders”)

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-009510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.